NASCAR Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B by January 8, 2024 by January 8, 2024 Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.… 0 FacebookTwitterPinterestEmail